Introduction
============

The use of drug eluting stents (DES) was a major breakthrough in reducing the risk of restenosis following stent-induced injury ([@B38]; [@B66]). DES utilize polymer excipients on the stent platform to deliver anti-proliferative drugs over several weeks to months ([@B13]). Current 2nd and 3rd generation DES have significantly improved clinical success as compared to 1st generation DES, with the incidence of restenosis falling below 10% ([@B67]; [@B39]). However, the clinical success of DES is limited to the coronary vasculature and does not translate to treatment of peripheral arterial disease (PAD) ([@B63]). Unlike the coronaries, stents in the periphery are subjected to biomechanical stress and risk of strut fracture ([@B54]). Fractured stents exert additional stresses on the artery wall and increase re-occlusion rates ([@B54]; [@B49]). Furthermore, small diameter peripheral vessels, often occluded in diabetic patients, are not conducive to stent intervention which precludes their use in below-the-knee applications. Revascularization of these arteries are essential for limb salvage in diabetic patients ([@B69]; [@B48]). These limitations of DES in the treatment of PAD have revived ideas of delivering anti-proliferative drugs without the use of a metallic stent platform leading to the advent of non-stent local drug delivery devices.

Drug coated balloons (DCB) have recently emerged as a new non-stent therapeutic approach to treat PAD ([@B78], [@B77]; [@B53]; [@B72],[@B73]). DCB are angioplasty balloons directly coated with an anti-proliferative therapeutic drug and excipient (drug carrier) to aid in drug transfer. DCB were approved for the treatment of PAD in 2009 in Europe and late 2014 in the United States. During this time, there have been a wide variety of excipients used ([@B56]; [@B11]; [@B12]; [@B25]; [@B53]; [@B59]). Excipients aid in many aspects of a DCB design, which includes: (1) enhancing adhesion of the drug to the balloon surface, (2) increasing stability of the drug coating during handling, (3) enhancing release of the drug coating during deployment, (4) increasing drug solvation, (5) maximizing binding of the drug coating to the vessel wall, and (6) sustaining a drug depot at the vessel surface ([@B12]; [@B76]; [@B9]; [@B60]; [@B30]; [@B33]; [@B65]). In the United States, DCB excipients include polysorbate and sorbitol, urea, polyethylene glycol (PEG), and butyryl-tri-hexyl citrate (BTHC). Other excipients used in Europe include dimethyl sulfoxide (DMSO) and shellac. Each excipient serves a different function. For example, polysorbate and PEG are known cosolvents of paclitaxel ([@B70]; [@B2]) and urea acts to increase paclitaxel release at the lesion ([@B12]). The most recently FDA-approved DCB, Spectranetics Stellarex^TM^, uses a PEG excipient shown to bind to hydroxyl apatite, a primary component of calcified atherosclerotic lesions ([@B76]; [@B33]; [@B59]; [@B65]). Though each of these excipients have led to improvements in clinical results as compared to non-coated balloon angioplasty, these outcomes hold much room for improvement ([@B78], [@B77]; [@B11]; [@B53]; [@B81]; [@B50]; [@B72],[@B73]). There exists still a need for a more durable, longer-lasting drug carrier to elongate arterial drug delivery and further inhibit neointimal hyperplasia and restenosis. As excipients are constantly evolving and improving, the function of excipients used also needs to expand.

Keratin, an endogenous structural protein found in hair and nails, is an increasing used biomaterial that has been demonstrated in a wide variety of applications including wound healing, ([@B46]; [@B44]) nerve repair, ([@B27]; [@B32]; [@B43]) treatment of myocardial infarction, ([@B61]) and hemostasis ([@B1]; [@B41]; [@B8]). Keratose, the oxidatively purified extract of keratin, has low toxicity and immunogenicity and can spontaneously forms scaffolds capable of eluting drugs/factors in a concentration-dependent manner ([@B26]; [@B15]; [@B52]; [@B7]). [@B52] demonstrated that release of ciprofloxacin from keratose is highly correlated to degradation of keratose. [@B23] also demonstrated correlation of IGF-1 release to keratin degradation. This *in vivo* degradation is mediated solely through hydrolytic degradation as there are no known mammalian keratinases ([@B37]). As such, keratins are a material of interest as drug delivery depots in tissue engineering strategies for drug delivery. However, to our knowledge, the ability to use keratose for the delivery of drugs from coatings of balloon has not previously been reported. The goal of this study was to thus evaluate the feasibility of a paclitaxel delivery via a keratose-paclitaxel drug coated balloon. Specifically, paclitaxel release was determined *in vitro* and arterial retention of paclitaxel was investigated using an *ex vivo* and a swine injury model. To our knowledge, this is the first use and evaluation of a biomaterial as an excipient to paclitaxel.

Materials and Methods {#s1}
=====================

Chemicals and Materials
-----------------------

Liquid paclitaxel (6 mg/mL) was purchased from Sagent Pharmaceuticals (Schaumburg, IL, United States). Powdered paclitaxel was purchased from LC Laboratories (Woburn, MA, United States). Sterile (2 MRad gamma irradiation), lyophilized keratose was obtained from KeraNetics LLC (Winston-Salem, NC, United States) and used without further modification and under aseptic conditions. Iohexol (OMNIPAQUE^TM^ \[300 mgI/mL\]) was purchased from GE Healthcare (Little Chalfont, United Kingdom). Docetaxel was purchased from Tocris Bioscience (Bristol, United Kingdom). DMSO, methanol, water, acetonitrile, and formic acid were procured through Sigma-Aldrich (St. Louis, MO, United States). Absolute ethanol 200-proof was purchased from Fisher Scientific (Hampton, NH, United States).

*In vitro* Keratose-Paclitaxel Degradation/Release
--------------------------------------------------

Paclitaxel-containing keratose hydrogels were formed at 12, 15, and 20% weight-to-volume ratios of keratose in phosphate buffered saline (PBS) (GE Healthcare Hyclone, Logan, UT, United States) as previously described ([@B75]). Hydrogels were injected into microcentrifuge tubes. The volume of each hydrogel (12, 15, and 20%) was 350 μL, each containing 500 μg of paclitaxel. Keratose-paclitaxel hydrogels were incubated at 37°C, 500 μL of 1× PBS was added on top of each hydrogel and at specified time points (up to 45 days) the PBS was removed for quantification and replaced with fresh PBS (**Figure [1A](#F1){ref-type="fig"}**).

![*In vitro* paclitaxel release from keratose hydrogels (one sample per each hydrogel). **(A)** Set-up for quantifying paclitaxel time-dependent release, **(B)** Cumulative degradation of keratose, and **(C)** Cumulative release of paclitaxel.](fphar-09-00808-g001){#F1}

### Quantification of Paclitaxel From *in vitro* Release

Paclitaxel was quantified from PBS samples containing keratose by high-performance liquid chromatography tandem mass spectrometry (HPLC-MS). Prior to HPLC-MS, keratose was removed from the samples by ethanol extraction ([@B75]). A Symmetry C18, 100 Å, 3.5 μm, 100 × 2.1 mm column (Waters Corporation, Milford, MA, United States) was used for separation. Using a previously developed HPLC-MS method, paclitaxel was quantified with an LTQ Velos Orbitrap Mass Spectrometer with Electrospray Ionization (Thermo Fisher Scientific, Waltham, MA, United States) run in positive ion mode ([@B75]). Paclitaxel was detected at 854 m/z. The internal standard, docetaxel, was detected at 808 m/z ([@B75]).

### Quantification of Keratose

Keratose samples were diluted at 1:1, 1:2, 1:4, and 1:6 in triplicate. Following the manufacturer's protocol, keratose was quantified in triplicate using the DC Protein Assay (Bio-Rad Laboratories, Hercules, CA, United States). Absorbance was measured with a SpectraFluor microplate reader (Tecan, Männedorf, Switzerland) at 750 nm.

Balloon Coating
---------------

Paclitaxel was prepared by dissolving in absolute ethanol followed by sonication at a final concentration of 40 mg/mL. Keratose solution was prepared by dissolving lyophilized keratose in iohexol at a 6% weight-to-volume ratio in iohexol. An in-house air spray coating method, via a Master Airbrush (TCP Global, San Diego, CA, United States), was used to deposit keratose and paclitaxel in a layered approach (**Figure [2](#F2){ref-type="fig"}**). Briefly, up to four balloons were mounted upright on a coating stand. Underneath a backdraft hood, keratose, paclitaxel, and keratose were air-spray coated in succession by loading a predetermined volume in the airbrush fluid cup. Moving the airbrush up and down the balloon(s) were coated on four sides to achieve a uniform coating circumferentially. For balloons sized 6 × 30 mm and 4.5 × 40 mm (Abbott Vascular, Abbott Park, IL, United States) 1 mL of keratose was used for each keratose layer and 7 mL of paclitaxel \[40 mg/mL\] for the paclitaxel layer. The layers were sprayed consecutively with no drying time between layers. The sprayer was cleaned in between each solution and following the final layer, the coated balloons were dried for a minimum of 1 h. Balloons were then sterilized by UV irradiation overnight.

![Air spray coating. **(A)** Master Airbrush coating system with TC-20 compressor, and 0.3 mm tip G22 high performance airbrush, **(B)** Coating of paclitaxel and keratose onto balloon surface -- balloons outlined by black ovals. **(C)** Non-coated angioplasty balloon. **(D)** Keratose-paclitaxel coated drug coated balloon.](fphar-09-00808-g002){#F2}

Scanning Electron Microscopy
----------------------------

Keratose-paclitaxel coated balloon segments and commercially available DCBs (Lutonix-Bard Peripheral Vascular, Tempe, AZ, United States and SeQuent Please, B. Braun Melsungen AG, Berlin, Germany) were cut from the catheter, mounted on studs, and sputter coated with gold palladium. A Quanta 250 scanning electron microscope with xT Microscope Control software (FEI, Hillsboro, OR, United States) was used for imaging.

Arterial Deployment
-------------------

Porcine carotid arteries from large pigs (250--350 lbs.) were harvested from a local abattoir. The arteries were transferred in sterile PBS with 1% antibiotic-antimitotic (Gibco, Grand Island, NY, United States), rinsed in sterile PBS in a culture hood and trimmed. Eight cm long segments were cut and tied with suture onto fittings within a bioreactor setup (**Figure [3](#F3){ref-type="fig"}**). The vessels were subjected to pulsatile flow as defined by a custom LabVIEW program as previously described ([@B4]). The flow medium was made up of Dulbecco's modified eagle's medium containing 10% fetal bovine serum and 1% antibiotic-antimycotic. Prior to deployment, vessel diameter was evaluated by ultrasound and vessels were denuded with balloon angioplasty (**Figure [3](#F3){ref-type="fig"}**). Keratose-paclitaxel coated DCB were deployed for 2 min at a 10--20% overstretch. At 1 h, flow was ceased and the treated portion of the vessel was removed. Excised vessels were flash frozen, stored at --80°C and shipped on dry ice to iC42 Clinical Research and Development (Aurora, CO, United States) for quantification of arterial paclitaxel.

![*Ex vivo* bioreactor system. **(A)** A gear pump generated pulsatile through explanted arteries within the CO2 incubator. **(B)** The explanted artery is bathed in cell culture media and an ultrasound probe can be directly placed on the outer sleeve of the bioreactor housing to measure the diameter. **(C)** Ultrasound image showing the inner diameter of the explanted artery (markers outlined in red).](fphar-09-00808-g003){#F3}

Residual Paclitaxel Following Deployment
----------------------------------------

Paclitaxel remaining on the balloon following *ex vivo* and *in vivo* deployment was quantified by sonication of the balloon in ethanol for 30 min and subsequent HPLC-MS.

Quantification of Paclitaxel Tissue Concentrations
--------------------------------------------------

Paclitaxel tissue concentrations were quantified using a validated, previously described high-performance liquid chromatography (HPLC)-electrospray ionization- tandem mass spectrometry system (LC-MS/MS) ([@B83]). The system was made up of a series 1260 HPLC system (Agilent Technologies, Santa Clara, CA, United States) and an AB Sciex 5000 triple-stage quadrupole mass spectrometer (AB Sciex, Concord, ON, Canada). Paclitaxel-D~5~ was purchased from Toronto Research Chemicals (Toronto, ON, Canada) to be used as the internal standard. Untreated pig arteries were used to prepare calibration curves consisting of paclitaxel concentrations ranging from 0.5 to 100 ng/mL ([@B4]).

Briefly, 100 μL of sample was injected onto a 4.6 ⋅ 12.5 mm 5 μm extraction column (Eclipse XDB C-8, 5 μm particle size, Agilent Technologies, Palo Alto, CA, United States) with a flow rate of 3 mL/min and a temperature of 65°C. Samples were then washed with a mobile phase of 15% methanol and 85% 0.1% formic acid. The flow was 3 mL/min and the temperature for the extraction column was set to 65°C. After 1 min of washing the samples with mobile phase (15% methanol; 85% 0.1% formic acid), the analytes were then back-flushed from the extraction column onto a 150 ⋅ 4.6 mm C8, analytical column (Zorbax XDB C8, 3.5 μm particle size, Agilent Technologies, Palo Alto, CA, United States). Paclitaxel was detected in the positive multi-reaction mode using the following ion transitions: m/z = 876.6 \[M+Na\]^+^ → 308.2. The internal standard, Paclitaxel-D~5~, was detected using the transition m/z = -881.6 \[M+Na\]^+^ → 313.1.

Porcine Ilio-Femoral Injury Model
---------------------------------

This study was approved by the Institutional Animal Care and Use Committee (IACUC) and conformed to the current Guide for the Care and Use of Laboratory Animals. Four female pigs (12.3--14.1 kg) were anesthetized and the right carotid artery was exposed under a sterile field. The caudal end of the right carotid artery was tied-off. Using micro scissors, a small incision was made to the right carotid artery and a 6 French (F) guide sheath was inserted. A NITREX^TM^ 0.014 guidewire (ev3 Inc., Plymouth, MN, United States) was inserted and, under fluoroscopic guidance, endothelial denudation using a 4 × 12 mm angioplasty balloon catheter (Abbot Vascular, Abbott Park, IL, United States) was performed to the left and right iliac arteries. Following denudation, 4.5 mm × 40 mm keratose-paclitaxel DCB were tracked to each of the iliac arteries and deployed for 2 min. Antiplatelet therapy consisted of aspirin (40 mg/day) given orally 24 h before catheterization with continued dosing throughout the in-life phase of the study, while single-dose intra-arterial heparin (150 IU/kg) and lidocaine were administered at the time of catheterization. Animals were anesthetized and euthanized by intravenous Fatal-Plus (Vortech Ltd., Dearborn, MI, United States) injection (85--150 mg/kg) at 1 h. Treated segments were excised following geographic landmarks determined by angiography. Excised arteries were stored at -80°C and, as aforementioned, shipped on dry ice to the bioanalytical laboratory for analysis (iC42 Clinical Research and Development, Aurora, CO, United States).

Statistical Analysis
--------------------

The data were presented as mean ± standard deviation. Data were compared with the Student *t*-test using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, United States). A value of *p* ≤ 0.05 was considered statistically significant.

Results
=======

Paclitaxel Release From Keratose Hydrogels
------------------------------------------

Centrifuge tubes were seeded with a mixture of keratose at concentrations of 12 to 20% (2 per each concentration; **Figure [1A](#F1){ref-type="fig"}**). Total paclitaxel was constant for all tubes, 500 μg each. Paclitaxel and keratose measurements were performed from 1 h to 45 days. To measure paclitaxel from keratose hydrogels, samples were diluted in PBS and read with a SpectraFluor plate reader. An HPLC-MS method developed by our group was used to quantify paclitaxel ([@B75]). Briefly, keratose was extracted from all samples by ethanol extraction with an extraction efficiency of 93.0 ± 3.4% ([@B75]). The method was validated by an intra- and inter-day precision of 4.3 and 7.9%, respectively. This precision is consistent with values for quantification of paclitaxel from plasma samples (1.04 and 12.3% RSD; [@B19]; [@B31]; [@B71]; [@B47]) and is effective in measuring paclitaxel concentrations from aqueous, keratin-containing samples.

Keratose degraded more quickly at a lower concentration of keratose and more slowly at a higher concentration of keratose (**Figure [1B](#F1){ref-type="fig"}**). The 12% keratose-paclitaxel degraded most rapidly with over 80% degradation at 45 days. The slower degradation was shown by the 20% keratose-paclitaxel hydrogel which degraded only 47% at 45 days. Paclitaxel release from keratose hydrogels showed similar gradients wherein the higher concentration of keratose released paclitaxel more slowly and the lower concentration of keratose released paclitaxel more rapidly (**Figure [1C](#F1){ref-type="fig"}**). The results confirm the ability of keratose to modulate release of paclitaxel *in vitro*.

Scanning Electron Microscopy
----------------------------

**Figure [4](#F4){ref-type="fig"}** displays SEM surface images of the keratose-paclitaxel, Sequent Please and Lutonix-Bard DCB. The keratose-paclitaxel and Lutonix-Bard DCB surfaces shows uniform coating, however, the Sequent Please displayed areas of sparse coating. Overall, the surface of the keratose-paclitaxel and Sequent Please show a rougher texture as compared to the Lutonix-Bard. The textured surface in the Sequent Please DCB can be observed on the surface and in the balloon folds region, whereas in the keratose-paclitaxel DCB the textured surface is uniformly distributed on the surface. The Lutonix-Bard DCB surface overall is very smooth (non-textured) with small circular rough patterns.

![Scanning electron micrograph of various drug coated balloons (DCB). **(A,B)** SEM images of keratose-paclitaxel DCB showing uniform textured coating. Red arrows indicate folding in the balloon. **(C,D)** SEM images of Sequent Please DCB showing a mixture of bare (non-coated) and textured coating. Regions of sparse coating exposing the surface of the balloon angioplasty is shown in blue arrows. Textured coating mostly notable within the folds of the balloon (red arrows). **(E,F)** SEM images of Lutonix-Bard DCB showing uniform smooth coating. Yellow arrow heads indicated circular droplet textures.](fphar-09-00808-g004){#F4}

*Ex vivo* and *in vivo* Assessment of Keratose DCB
--------------------------------------------------

Commercially available non-coated angioplasty balloons were successfully coated with a keratose-paclitaxel mixture (**Figure [2](#F2){ref-type="fig"}**). For the *ex vivo* model, DCB were inserted through a 5 Fr sheath into a closed-circulatory system with physiological parameters (put pressure and flow rates). Following diameter ultrasound imaging of the harvested arteries, DCB were deployed at a balloon-to-artery ratio ranging from 1.1 to 1.2:1.0 for 1 min. Treated sections were clearly marked during inflation on the bioreactor, and following 1 h, treated section of the arteries were removed and analyzed for arterial tissue paclitaxel concentration (see **Table [1](#T1){ref-type="table"}**). Pharmacokinetic evaluation of the *ex vivo* arteries demonstrated a paclitaxel concentration at 1 h was 43.60 ± 14.8 ng/mg (*n* = 4). Residual paclitaxel, remaining paclitaxel on the DCB following deployment *ex vivo*, was 10.51 ± 9.8% (*n* = 4).

###### 

Comparison of *ex vivo* and *in vivo* arterial paclitaxel levels following keratose-paclitaxel DCB delivery.

  Testing Model   Paclitaxel (ng/mg)   *p*-value
  --------------- -------------------- -----------
  *Ex vivo*       43.60±14.8           0.71
  *In vivo*       56.60±66.4           
                                       

To further demonstrate the keratose coating to delivery paclitaxel to arteries, and to confirm the *ex vivo* results, keratose-paclitaxel DCB were deployed in a swine femoral injury model (**Figure [5](#F5){ref-type="fig"}**). The target balloon-to-artery ratio was 1.1--1.2:1.0 with an inflation time of 1 min. The time from insertion into the blood stream to the deployment site was less than 1 min. All treated arteries were free of dissection or any acute thrombotic event as determined by angiography. Following 1 h, treated arteries were explanted and analyzed by pharmacokinetics. The exact location of treatment was identified by anatomical landmarks (**Figure [5](#F5){ref-type="fig"}**). Paclitaxel drug level at 1 h was 56.6 ± 66.4 ng/mg (*n* = 3). Residual paclitaxel of DCB following deployment *in vivo* was 12.77 ± 9.4% (*n* = 3). In comparing *in vivo* and *ex vivo* arterial paclitaxel results, similar arterial paclitaxel levels were measured at 1 h (56.6 ± 66.4 ng/mg vs. 43.60 ± 14.8 ng/mg, *p* = 0.71).

![*In vivo* deployment of DCB. **(A)** Angiographic image of the ilio-femoral artery of the *in vivo* pig model. **(B)** Angiographic image of the DCB in its deployed state. **(C)** Gross image of the explant site of the treated arterial segment (yellow arrow indicates treatment site).](fphar-09-00808-g005){#F5}

Discussion
==========

This study evaluates, for the first time, the use of keratose as an excipient of paclitaxel for development of a novel DCB. The ability of keratose to deliver/release paclitaxel in a keratose-concentration dependent manner was first confirmed in an *in vitro* setup and quantified by a previously validated, in-house HPLC-MS method ([@B75]). A custom coating method resulted in uniform coating of angioplasty balloons with a keratose-paclitaxel coating. An *ex vivo* model demonstrated the ability of the keratose-paclitaxel DCB to transfer drug to arterial tissue at 1 h. Pharmacokinetic analysis of treated pig arteries *in vivo* confirmed *ex vivo* results and confirmed the presence of paclitaxel at therapeutic levels. Overall, these results demonstrate the feasibility to deliver paclitaxel via a keratose-paclitaxel DCB.

Non-stent delivery platforms, such as DCB, are seen as a next generation approach to overcome the limitations of stents in the treatment of PAD ([@B10]). Stents in the periphery are subject to biomechanical stress increasing the risk of fracture, leading to device failure ([@B54]; [@B40]; [@B14]). The primary advantage of DCB is the uniformity and short-term transfer of drug to the luminal surface without the need of a stent platform and a polymer carrier ([@B55]). The success of DCB in PAD treatment has been shown in several randomized clinical trials, demonstrating superiority of this technology over standard non-coated balloons (i.e., plain old balloon angioplasty, POBA) in the treatment of femoropopliteal (above-the-knee) arteries ([@B77]; [@B53]; [@B50]; [@B72]). To date, most clinical studies demonstrate the benefit of DCB up to 12 months in relatively short lesions, with few studies reporting follow-ups longer than 1 year ([@B74], [@B72]; [@B77]; [@B36]; [@B53]; [@B50]; [@B59]). In one of the only long-term (2 year) real-world registries, results suggest that DCB are safe and effective in delaying rather than preventing restenosis in long, complex lesions of the femoropopliteal (above-the-knee) region ([@B58]). For the treatment of infrapopliteal (below-the-knee) disease, DCB have shown to be less effective with no clinical benefit over standard non-coated balloons ([@B81]; [@B82]). These clinical studies confirm the benefits of DCB clinically, however, improvements to DCB are needed to recover long-term clinical results. One such target for long-term clinical success is long-term paclitaxel retention at the artery by careful selection of excipients to modulate such retention.

Current generation of DCB primarily use the anti-proliferative drug paclitaxel. Paclitaxel, which is extracted from pacific yew bark, inhibits cell division by binding to growing microtubules ([@B51]). Used as a cancer therapeutic since 1992, paclitaxel is active against ovarian cancer, breast cancer, Kaposi's sarcoma, and lung cancer ([@B51]; [@B42]). More recently, paclitaxel has been used as an anti-restenotic in cardiovascular interventions such as DES and DCBs to inhibit smooth muscle cell proliferation -- a primary contributor to restenosis ([@B68]; [@B5]; [@B22]; [@B34]). The most advantageous aspect of paclitaxel as compared to other currently available anti-proliferative agents is that it is highly potent and has shown to be effective in the short, single dose approach ([@B64]). However, paclitaxel is highly lipophilic and nearly insoluble in water, and has shown to be more effective when delivered with excipients as compared to paclitaxel alone in treatment of vascular disease ([@B56],[@B57]; [@B4]).

The role of excipients in DCB serves many functions. First, excipients aid in adherence of the coating to the balloon itself. Upon arrival at the lesion, excipients aide in release of the coating from the balloon, deposition of the coating at the vessel surface, and uptake of the drug into the surrounding tissue. Finally, the excipient/drug must stay in place at the lesion, upholding the drug deposit and continuing drug elution into the tissue. DCBs are susceptible to loss of the drug coating during balloon tracking and deployment ([@B29]). Additionally, drug deposited at the vessel post-deployment is subjected to wash-off into the blood stream, further decreasing the long-term drug residency. Therefore, improved excipients to paclitaxel are crucial in decreasing drug loss during tracking and wash-off into the blood stream thereby improving drug residency and success of treatment. Here, keratose demonstrated a tunable release of paclitaxel as a function of keratose concentration *in vitro*. The novelty of tunable release of paclitaxel as a function of keratose lies in the ability to adjust keratose concentration to facilitate paclitaxel release in a time-dependent fashion relative to the restenotic cascade. It is hypothesized that this release is based on encapsulation or electrostatic forces of paclitaxel within the keratose scaffold ([@B52]). This tuned-release ability of keratose has also been demonstrated previously in antibiotic delivery and has potential in further applications where release kinetics need to be adjusted ([@B52]). Scaffolds made by lyophilized keratose hydrogels have been shown to contain cylindrical casts made up of isolated and interconnected pores ([@B15]). Further studies are warranted to determine the precise mechanism of paclitaxel release.

Keratin, the non-oxidized form of keratose, have shown to be safe in a variety of biomedical applications including skin ([@B45]), hemostasis ([@B7]), bone ([@B17]), nerve regeneration ([@B62]) and in the use of therapeutic delivery including antibiotics ([@B52]) and recombinant human bone morphogenetic protein ([@B16]). In a recent paper by Han et al., the degradation of keratin did not increase levels of toxicity due to changes in the protein or due to the presence of residual iodoacetamide ([@B24]). For the *in vitro* studies, we examined paclitaxel release from keratose concentrations varying from 12 to 20%. This was done primarily to determine correlation between paclitaxel release and the rate of keratose degradation based on previously reported methods ([@B52]; [@B23]). And although the *in vitro* studies did confirm the ability of keratose to modulate release of paclitaxel, for balloon coating purposes, the keratose concentration was reduced to 6%. This deviation of concentration was necessary as the 6% keratose concentration did not gel, and thus remained in liquid form enabling us to successfully spray coat our uncoated balloons and examine the feasibility of paclitaxel transfer of a keratose-paclitaxel coated balloon. Specifically, we wanted to determine if the arterial paclitaxel levels following delivery was within the therapeutic target ranging from 0.01 to 100 ng/mg (paclitaxel amount/weight of arterial tissue; [@B5]; [@B9]). Our *in vivo* results demonstrated arterial paclitaxel levels of 56.6 ± 66.4 ng/mg (*n* = 3) at 1 h. These results were similar to preclinical evaluation of a FDA-approved DCB with paclitaxel levels of 58.8 ± 54.2 ng/mg at 1 h ([@B80]). Angiography showed no sign of thrombus following DCB deployment. It is important to note keratose, extracted from keratin via oxidative extraction, used in these studies is known to be non-thrombogenic ([@B15]). However, reductively extracted keratin (known as kerateine) has an entirely different effect in that it is thrombogenic ([@B26]). Thus, it is not the primary protein sequence of keratin that leads to the observed effects, but rather a combination of properties of the amino acids in the primary protein structure based on its method of extraction and the properties of the keratin solutions or hydrogels. However, the properties of the hydrogels are indeed due largely to the primary amino acid properties including isoelectric point and ability to form covalent crosslinks via thiol groups. A salient feature of keratins is the presence of a large number of cysteine residues within the primary sequence. Thiol groups on cysteine amino acid residues become available for disulfide crosslinking in kerateine obtained by oxidative extraction but not in keratose where oxidative extraction leads to sulfonic acid groups on cysteine residues.

Pharmacokinetic evaluation is accepted as the gold standard method to evaluate DCB ([@B35]; [@B21]; [@B80]; [@B18]; [@B20]; [@B65]). The current paradigm for evaluating DCB is relatively non-existent prior to animal testing. Bench testing of non-stent devices (such as DCB and perfusion catheters) are confined to mechanical testing of the balloon (burst pressure, fatigue), tracking and particulate matter, and biocompatibility of the drug and carrier using cell culture and static techniques ([@B6]; [@B28]; [@B3]). *In vitro*, the total drug coated on a balloon can be quantified as well as elution from the balloon into a saline bath of controlled volume, however, the transfer of the drug from the device to an artery (arterial uptake and retention) is lacking. It is these limitations that drug delivery parameters are tested and verified *in vivo* by removing treated vessels at several time points to determine the acute transfer of drug and drug retention. Although these trials are essential in determining drug delivery, they are often very long, costly, and utilize a large number of animals. The developed *ex vivo* bioreactor system described here permits the use of explanted living native pig arteries to be used as the test section. Previously we have shown that harvested swine arteries maintain functionality up to 7 days *ex vivo* ([@B79]). This is particularly important because there are currently no man-made vessels that can duplicate the cellular organization, structure, and elasticity of the native artery. Furthermore, the explanted arteries can mimic the acute transfer of the drug from the device, which is the most significant aspect of DCB platforms.

Other benefits of our *ex vivo* system include the ability to evaluate any commercially available vascular device, running multiple experiments simultaneously, obtaining the results in days, and the low cost associated with performing *ex vivo* experiments as compared to *in vivo* experiments. Additionally, due to the design of the system, the inner diameter of the explanted arteries can be monitored and measured using ultrasound (**Figure [3](#F3){ref-type="fig"}**). This is particularly important for deployment of balloons and stents as they are designed to be inflated in respect to the vessel diameter. Under deployment or over deployment of these devices directly affect and can alter drug transfer to the artery.

The keratose-paclitaxel DCBs lacked coating within the balloon folds. To achieve coating within the folds of the balloon, the balloon must be coated in the deployed state and then carefully refolded. Refolding of the coated balloon requires use of a very costly piece of equipment which precisely refolds the balloons. Due to the lack of coating within the folds of the balloons in this study the drug distribution following deployment is not uniform circumferentially. Despite this limitation, arterial transfer and uptake of paclitaxel can still be quantified. Pharmacokinetics *in vivo* were evaluated in healthy and not diseased arteries. It was decided not to use a disease model because this is the first instance that keratose has been used as an excipient for vascular drug delivery and was therefore a proof-of-concept study. It was crucial to test the keratose-paclitaxel balloon in a non-disease model at this time because the complexities of a disease model may mask keratose-specific effects. In addition, no off-the shelf products were evaluated for a side by side comparison. Longer time points *in vivo* should be assessed to evaluate long-term pharmacokinetics and histology of the keratose-paclitaxel balloon. Some limitations of our system include the fact that culture medium was the working fluid rather than whole blood. The generated *ex vivo* flow conditions did not duplicate *in vivo* conditions. Another limitation of the current studies includes the inflicted damage to cells during the carotid artery harvest. In spite of these limitations, evaluation of the pharmacokinetics can be accomplished. Off-the-shelf vascular devices can be inserted, conditioned at physiological mechanical conditions in a native artery *ex vivo*, and evaluated for drug pharmacokinetics.

To conclude, this study provides the first evidence of the use of keratose as a novel excipient to coat DCB. Pharmacokinetic studies demonstrated therapeutic levels of paclitaxel at 1 h in arteries treated with a keratose-paclitaxel coating *ex vivo* and *in vivo*. Novel excipients, such as keratose, can potentially improve upon the focus of current excipients which are designed to increase solubility of paclitaxel and penetration of the drug to long-term sustained drug. Further studies are warranted to demonstrate such benefits of keratose. Safety of the keratose-paclitaxel DCB can be assessed by delivery of 2× or 4× dose *in vivo* followed by histological evaluation. Overall, this approach has the potential to improve interventional outcomes and quality of life of millions of patients suffering with PAD.
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